The Bt-DUX: development of a subjective measure of health-related quality of life in patients who underwent surgery for lower extremity malignant bone tumor.

abstract：:Risk-adapted, response-based therapies for pediatric Hodgkin lymphoma have resulted in 5-year survival exceeding 90%. Although high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) are considered standard for most patients with relapsed or refractory Hodgkin lymphoma, a subset of childr...

journal_title：Pediatric blood & cancer

authors： Harker-Murray PD,Drachtman RA,Hodgson DC,Chauvenet AR,Kelly KM,Cole PD

更新日期：2014-04-01 00:00:00

abstract：BACKGROUND:Children with sickle cell disease (SCD) are at increased risk of death from invasive bacterial infections. Emergent evaluation of fever allows early treatment of potentially fatal infections. Limited data exist regarding caregiver adherence to physician recommendations of prompt medical evaluation of fever i...

journal_title：Pediatric blood & cancer

authors： Schultz CL,Tchume-Johnson T,Schapira MM,Bellamy S,Smith-Whitley K,Ellison A

更新日期：2015-11-01 00:00:00

abstract：BACKGROUND:Primary mediastinal germ cell tumors (GCTs) are rare in children and still represent a challenge for both adult and pediatric oncologists because of their worse outcome compared to their gonadal counterpart. PROCEDURE:Prospectively collected data concerning patients enrolled in the Italian Association of Pe...

journal_title：Pediatric blood & cancer

authors： De Pasquale MD,Crocoli A,Conte M,Indolfi P,D'Angelo P,Boldrini R,Terenziani M,Inserra A

更新日期：2016-05-01 00:00:00

abstract：BACKGROUND:Griscelli syndrome type 2 (GS2), the X-linked lymphoproliferative (XLP) and the Chédiak-Higashi (CHS) syndromes are diseases that all may develop hemophagocytic syndromes. We wanted to investigate whether the treatment protocols for hemophagocytic lymphohistiocytosis (HLH) can also be used for these syndrome...

journal_title：Pediatric blood & cancer

authors： Trottestam H,Beutel K,Meeths M,Carlsen N,Heilmann C,Pasić S,Webb D,Hasle H,Henter JI

更新日期：2009-02-01 00:00:00

abstract：:As a sympathetic nervous system-derived tumor, aggressive neuroblastoma (NB) is currently attracting interest from researchers seeking diagnostic and prognostic markers via less invasive procedures. The analysis of circulating tumor DNA (ctDNA) in peripheral blood can provide genetic information from multiple tumor le...

journal_title：Pediatric blood & cancer

authors： Wei M,Ye M,Dong K,Dong R

更新日期：2020-10-01 00:00:00

abstract：:Imatinib can be safely discontinued in adults with chronic myeloid leukemia (CML) where there is a prolonged complete molecular response (CMR). No data are available in the pediatric population. Six children with CML discontinued imatinib by themselves. Only three of them were in CMR but for <2 years. A significant in...

journal_title：Pediatric blood & cancer

authors： Millot F,Claviez A,Leverger G,Corbaciglu S,Groll AH,Suttorp M

更新日期：2014-02-01 00:00:00

abstract：BACKGROUND:Despite the increasing cure rates for children with acute lymphoblastic leukemia (ALL), patients who relapse continue to have poor prognosis. The Children's Oncology Group (COG) conducted a limited institution Phase II trial of Campath-1H, a monoclonal antibody that targets CD52 on leukemic cells, in childre...

journal_title：Pediatric blood & cancer

authors： Angiolillo AL,Yu AL,Reaman G,Ingle AM,Secola R,Adamson PC

更新日期：2009-12-01 00:00:00

abstract：BACKGROUND:Hematopoietic stem cell transplant (HSCT) can cure or alleviate a wide range of nonmalignant childhood conditions. However, few studies have examined longitudinal national trends of frequency or short-term complications of HSCT before 2006 when an HSCT became a reportable procedure by US law. By using a US n...

journal_title：Pediatric blood & cancer

authors： Takahashi T,Pereda MA,Bala N,Nagarajan S

更新日期：2019-06-01 00:00:00

abstract：:Germline DICER1 pathogenic variants predispose to numerous benign and malignant tumors. In this report, we describe DICER1 gene analysis in an adolescent diagnosed with multinodular goiter, ovarian Sertoli-Leydig cell tumor, and lung cyst. DICER1 mutational screening at the DNA level failed to detect any pathogenic va...

journal_title：Pediatric blood & cancer

authors： Verrier F,Dubois d'Enghien C,Gauthier-Villars M,Bonadona V,Faure-Conter C,Dijoud F,Stoppa-Lyonnet D,Houdayer C,Golmard L

更新日期：2018-06-01 00:00:00

abstract：BACKGROUND:The level of minimal residual disease (MRD) prior to allogeneic hematopoietic stem cell transplantation (HSCT) has been shown to be an independent prognostic factor for outcome of pediatric patients with high-risk acute lymphoblastic leukemia (ALL). Retrospective studies which used (semi-) quantitation of cl...

journal_title：Pediatric blood & cancer

authors： Sramkova L,Muzikova K,Fronkova E,Krejci O,Sedlacek P,Formankova R,Mejstrikova E,Stary J,Trka J

更新日期：2007-01-01 00:00:00

abstract：:The FIP1L1-PDGFRA fusion gene is the most frequent genetic aberration in myeloid neoplasms associated with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1. Affected patients in adult populations are very sensitive to imatinib therapy. Pediatric cases are rare and so far only one case of FIP1L1-PDGFRA positi...

journal_title：Pediatric blood & cancer

authors： Rathe M,Kristensen TK,Møller MB,Carlsen NL

更新日期：2010-10-01 00:00:00

abstract：:A 6-year-old female was admitted with abdominal pain and a mass in the right abdomen. Her lactose dehydrogenase level was 1,200 IU/L, and neuron specific enolase was 120 ng/ml. Computed tomography scan confirmed a large right renal mass with necrosis. A right radical nephrectomy was performed. The tumor was completely...

journal_title：Pediatric blood & cancer

authors： Maeda M,Tsuda A,Yamanishi S,Uchikoba Y,Fukunaga Y,Okita H,Hata J

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:A pediatric Phase I trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetics (PK) of vorinostat and bortezomib, in patients with solid tumors. PROCEDURE:Oral vorinostat was administered on days 1-5 and 8-12 of a 21-day cycle (starting dose 180 mg/m(2...

journal_title：Pediatric blood & cancer

authors： Muscal JA,Thompson PA,Horton TM,Ingle AM,Ahern CH,McGovern RM,Reid JM,Ames MM,Espinoza-Delgado I,Weigel BJ,Blaney SM

更新日期：2013-03-01 00:00:00

abstract：BACKGROUND:We investigated the spectrum, frequency, and risk factors for renal, gastrointestinal, and hepatic late adverse effects in survivors of childhood acute myeloid leukemia (AML) without relapse treated with chemotherapy alone according to three consecutive AML trials by the Nordic Society of Pediatric Hematolog...

journal_title：Pediatric blood & cancer

authors： Skou AS,Glosli H,Jahnukainen K,Jarfelt M,Jónmundsson GK,Malmros-Svennilson J,Nysom K,Hasle H,Nordic Society of Pediatric Hematology and Oncology.

更新日期：2014-09-01 00:00:00

abstract：BACKGROUND:Pediatric health-related quality of life (HRQOL) questionnaires have been validated in children with sickle cell disease (SCD), but small sample sizes in these studies have limited clinical comparisons. We used the baseline clinical data from the Collaborative Data (C-Data) Project of the Comprehensive Sickl...

journal_title：Pediatric blood & cancer

authors： Dampier C,Lieff S,LeBeau P,Rhee S,McMurray M,Rogers Z,Smith-Whitley K,Wang W,Comprehensive Sickle Cell Centers (CSCC) Clinical Trial Consortium (CTC).

更新日期：2010-09-01 00:00:00

abstract：BACKGROUND:Numerous recent reports have described the use of recombinant factor VIIa (rFVIIa) in non-hemophilia bleeding situations for achievement of hemostasis. However, its use in clinical situations other than hemophilia patients with inhibitors has been complicated by some reports of thrombotic events. rFVIIa has ...

journal_title：Pediatric blood & cancer

authors： Puetz J,Darling G,Brabec P,Blatny J,Mathew P

更新日期：2009-12-01 00:00:00

abstract：BACKGROUND:Children less than 5 years of age with malignant central nervous system (CNS) tumors, continue to have a high rate of morbidity and mortality following administration of conventional therapy. In an attempt to avoid the neurologic sequelae associated with craniospinal radiation, strategies such as high-dose c...

journal_title：Pediatric blood & cancer

authors： Choi LM,Rood B,Kamani N,La Fond D,Packer RJ,Santi MR,Macdonald TJ

更新日期：2008-05-01 00:00:00

abstract：BACKGROUND:The improved survival rates for childhood acute lymphoblastic leukemia (ALL) may be jeopardized by the development of a second cancer, which has been associated with thiopurine therapy. PROCEDURE:We retrospectively analyzed three sequential Nordic Society of Paediatric Haematology and Oncology's protocols c...

journal_title：Pediatric blood & cancer

authors： Nielsen SN,Eriksson F,Rosthoej S,Andersen MK,Forestier E,Hasle H,Hjalgrim LL,Aasberg A,Abrahamsson J,Heyman M,Jónsson ÓG,Pruunsild K,Vaitkeviciené GE,Vettenranta K,Schmiegelow K

更新日期：2017-10-01 00:00:00

abstract：BACKGROUND:Based on the presumed clinical similarity between the two most severe sickle cell disease (SCD) genotypes, hemoglobin (Hb) Sβ0 thalassemia and HbSS, randomized controlled trials (RCTs) have included both genotypes. Our group has demonstrated that healthcare providers inadequately distinguish the two diagnose...

journal_title：Pediatric blood & cancer

authors： Day ME,Rodeghier M,DeBaun MR

更新日期：2018-11-01 00:00:00

abstract：BACKGROUND:The Children's Oncology Group (COG) publishes consensus guidelines with screening recommendations for early identification of treatment-related morbidities among childhood cancer survivors. We sought to estimate the yield of recommended yearly urinalysis screening for genitourinary complications as per Versi...

journal_title：Pediatric blood & cancer

authors： Ramirez MD,Mertens AC,Esiashvili N,Meacham LR,Wasilewski-Masker K

更新日期：2016-05-01 00:00:00

abstract：BACKGROUND:The neurokinin-1 receptor antagonist aprepitant, plus a 5HT3 antagonist and corticosteroid is well-tolerated and effective in preventing chemotherapy-induced nausea and vomiting in adults but has not been formally assessed in adolescents. PROCEDURE:Patients age 11-19 years old receiving emetogenic chemother...

journal_title：Pediatric blood & cancer

authors： Gore L,Chawla S,Petrilli A,Hemenway M,Schissel D,Chua V,Carides AD,Taylor A,Devandry S,Valentine J,Evans JK,Oxenius B,Adolescent Aprepitant in Cancer Study Group.

更新日期：2009-02-01 00:00:00

abstract：:Pediatric cancer survivors have increased risk of obesity, hypertension, dyslipidemia, and type 2 diabetes, leading to premature cardiovascular disease (CVD). Multiple tissues that are involved in glucose homeostasis and lipid metabolism are adversely affected by chemotherapy. This review highlights the relevant tissu...

journal_title：Pediatric blood & cancer

authors： Rosen GP,Nguyen HT,Shaibi GQ

更新日期：2013-12-01 00:00:00

abstract：:Survivorship care is a major area of focus in the holistic management of childhood cancer with current knowledge and information almost exclusively from high-income countries. In this review, we summarize the state of scientific knowledge, service delivery, advocacy initiatives, and research efforts in this field in I...

journal_title：Pediatric blood & cancer

authors： Arora RS,Arora PR,Seth R,Sharma S,Kumar C,Dhamankar V,Kurkure P,Prasad M

更新日期：2020-09-01 00:00:00

abstract：:Evidence of the laboratory benefits of hydroxyurea and its clinical efficacy in reducing acute vaso-occlusive events in adults and children with sickle cell anemia has accumulated for more than 15 years. A definitive clinical trial showing that hydroxyurea can also prevent organ damage might support widespread use of ...

journal_title：Pediatric blood & cancer

authors： Thompson BW,Miller ST,Rogers ZR,Rees RC,Ware RE,Waclawiw MA,Iyer RV,Casella JF,Luchtman-Jones L,Rana S,Thornburg CD,Kalpatthi RV,Barredo JC,Brown RC,Sarnaik S,Howard TH,Luck L,Wang WC

更新日期：2010-02-01 00:00:00

abstract：:Children with primary immunodeficiency or chromosomal breakage syndromes are at increased risk of developing non-Hodgkin lymphomas; they cannot tolerate standard chemotherapy regimens. We report two children with diffuse, large, B-cell lymphoma; one had ataxia telangiectasia and one had common variable immunodeficienc...

journal_title：Pediatric blood & cancer

authors： Shabbat S,Aharoni J,Sarid L,Ben-Harush M,Kapelushnik J

更新日期：2009-05-01 00:00:00

abstract：:A 6-year-old male with chronic granulomatous disease, who was transplanted with bone marrow and exhibited increasing mixed chimerism, subsequently received two donor lymphocyte infusions (DLI). Two weeks after the second DLI, the patient developed acute graft-versus-host disease (GVHD) and progressive pancytopenia tha...

journal_title：Pediatric blood & cancer

authors： Kato I,Umeda K,Awaya T,Yui Y,Niwa A,Fujino H,Matsubara H,Watanabe K,Heike T,Adachi N,Endo F,Mizukami T,Nunoi H,Nakahata T,Adachi S

更新日期：2010-02-01 00:00:00

abstract：:Minimal residual disease (MRD) is an independent predictor of relapse risk in children with leukemia and is widely used for risk-adapted treatment. This article summarizes current evidence supporting the use of MRD, including clinical significance, current international clinical practice, impact statement, and recomme...

journal_title：Pediatric blood & cancer

authors： Athale UH,Gibson PJ,Bradley NM,Malkin DM,Hitzler J,POGO MRD Working Group.

更新日期：2016-06-01 00:00:00

abstract：:Here, we present the case of a pediatric patient with newly diagnosed hepatocellular carcinoma causing central biliary obstruction and persistently elevated bilirubin of 3.0-4.3 mg/dl despite placement of bilateral internal-external biliary drains. The tumor was not resectable, and the patient was not a candidate for ...

journal_title：Pediatric blood & cancer

authors： Hiniker SM,Rangaswami A,Lungren MP,Thakor AS,Concepcion W,Balazy KE,Kovalchuk N,Donaldson SS

更新日期：2017-06-01 00:00:00

abstract：BACKGROUND:Children and adolescents with Non-Hodgkin lymphoma (NHL) and mature B-cell leukemia (B-ALL) have an excellent prognosis with contemporary chemotherapy stratified according to the histologic subtype and clinical stage of disease. However, a small subset of patients does not respond to front-line therapy or su...

journal_title：Pediatric blood & cancer

authors： Attarbaschi A,Dworzak M,Steiner M,Urban C,Fink FM,Reiter A,Gadner H,Mann G

更新日期：2005-01-01 00:00:00

abstract：BACKGROUND:Ensuring adequate parental consent is a key issue of ethical practice in pediatric oncology. In Germany, however, knowledge about parental comprehension and satisfaction with the informed consent procedure is limited, and representative data on parents' perspectives are still missing. Based on data collected...

journal_title：Pediatric blood & cancer

authors： Petersen I,Spix C,Kaatsch P,Graf N,Janka G,Kollek R

更新日期：2013-03-01 00:00:00